dsip sbir topics Air Force removes from SBIR/STTR solicitation | Kirk Macolini posted on the topic SBIR 101 - Center for

Lab markers (fasting glucose, insulin, lipid panel) typically show meaningful improvement

Lymphir, Citius first FDA-approved product, is a reformulation of the FDA-approved cancer treatment denileukin diftitox, which combines the IL-2 cytokine and the diphtheria toxin

Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157

Researchers believe that amylin analogues may eventually be paired with multiple GLP 1s, not only semaglutide, creating even more combination therapies in the future